CompletedEUCTR 2011-005179-18
A Double-blind, Placebo-controlled Study of Cariprazine (RGH-188) as Adjunctive Therapy In Major Depressive Disorder.
This historical record does not confirm current site availability.
Historical research recordMultiple countriesDepression
Understand this study
What did researchers investigate?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
Who was this study for?
This study was for people with depression. Other eligibility criteria applied.
- Listed locations
- Estonia · Finland and 2 more locations
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateNot clearly listed
- Recruitment status
- Completed
- Enrollment listed in the registry
- 810
- Sponsor
- Forest Research Institute, Inc
- Sponsor type
- Research institute
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Estonia, Finland, Slovakia, ...
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2011-005179-18
- Official title
Show the full official title
A Double-blind, Placebo-controlled Study of Cariprazine (RGH-188) as Adjunctive Therapy In Major Depressive Disorder.
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Estonia · Finland · Slovakia
1 more locations
- Sweden
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Forest Research Institute, Inc, a research institute.
Who was this study for?
This study was for people with depression. Other eligibility criteria applied.
